|
US6464978B1
(en)
|
1989-03-21 |
2002-10-15 |
The Immune Response Corporation |
Vaccination and methods against multiple sclerosis resulting from pathogenic responses by specific T cell populations
|
|
US5837246A
(en)
*
|
1989-03-21 |
1998-11-17 |
The Immune Response Corporation |
Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
|
|
US6221352B1
(en)
|
1989-03-21 |
2001-04-24 |
The Immune Response Corporation |
Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells
|
|
US5612035A
(en)
*
|
1989-03-21 |
1997-03-18 |
The Immune Response Corporation |
Vaccination against diseases resulting from pathogenic responses by specific T cell populations
|
|
US6113903A
(en)
*
|
1989-03-21 |
2000-09-05 |
The Immune Response Corporation |
Peptides and methods against diabetes
|
|
US6207645B1
(en)
*
|
1989-03-21 |
2001-03-27 |
The Immune Response Corporation |
Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
|
|
US6007815A
(en)
*
|
1989-03-21 |
1999-12-28 |
The Immune Response Corporation |
Anti-idiotype vaccination against diseases resulting from pathogenic responses by specific T cell populations
|
|
US6413516B1
(en)
*
|
1989-03-21 |
2002-07-02 |
The Immune Response Corporation |
Peptides and methods against psoriasis
|
|
US5861164A
(en)
*
|
1989-03-21 |
1999-01-19 |
The Immune Response Corporation |
Vaccination against diseases resulting from pathogenic responses by specific T cell populations
|
|
DE69121099T3
(de)
†
|
1990-05-01 |
2001-01-25 |
The Board Of Trustees Of The Leland S. Stanford Junior University, Stanford |
Stoffgemische zur Anwendung in einem Verfahren zur Behandlung eines an multipler Sklerose leidenden Menschen
|
|
JPH06507384A
(ja)
*
|
1991-01-22 |
1994-08-25 |
ザ イミューン レスポンス コーポレイション |
特定のｔ細胞群による病理的応答により生じる疾患に対するワクチン投与および方法
|
|
CA2110055C
(en)
*
|
1991-05-31 |
2002-08-20 |
Arthur A. Vandenbark |
T cell receptor peptides as therapeutics for immune-related disease
|
|
WO1993004695A1
(en)
*
|
1991-08-28 |
1993-03-18 |
The Wistar Institute |
T cell receptor-based therapy for rheumatoid arthritis
|
|
JPH06511241A
(ja)
*
|
1991-09-23 |
1994-12-15 |
ジェネンテク，インコーポレイテッド |
自己免疫疾患の診断および治療
|
|
EP0623025A1
(en)
*
|
1991-12-24 |
1994-11-09 |
The Immune Response Corporation |
Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
|
|
US6045796A
(en)
*
|
1992-12-17 |
2000-04-04 |
Anergen, Inc. |
Vaccination with peptide of MHC class II molecules for treatment of autoimmune disease
|
|
GB9325182D0
(en)
*
|
1993-12-08 |
1994-02-09 |
T Cell Sciences Inc |
Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
|
|
AU1812095A
(en)
*
|
1994-02-23 |
1995-09-11 |
Akzo Nobel N.V. |
A t cell receptor sequence specifically associated with an immune disease
|
|
DE4408999A1
(de)
*
|
1994-03-16 |
1995-09-28 |
Braun Melsungen Ag |
Humane T-Zellrezeptoren zur diagnostischen sowie therapeutischen Verwendung bei autoimmunem Diabetes mellitus
|
|
GB9423085D0
(en)
*
|
1994-11-16 |
1995-01-04 |
Stringer Bradley M J |
Targeted T lymphocytes
|
|
NZ514914A
(en)
|
1999-05-07 |
2004-09-24 |
Genentech Inc |
Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
|
|
CA2411102A1
(en)
|
2000-06-20 |
2001-12-27 |
Idec Pharmaceutical Corporation |
Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
|
|
US20020159996A1
(en)
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
|
AU2002237972B2
(en)
|
2001-01-31 |
2007-11-29 |
Biogen Idec Inc. |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
|
WO2002099385A2
(en)
|
2001-06-07 |
2002-12-12 |
Pionneer Hi-Bred International, Inc. |
Qtl controlling sclerotinia stem rot resistance in soybean
|
|
DE60332957D1
(de)
|
2002-12-16 |
2010-07-22 |
Genentech Inc |
Immunoglobulinvarianten und deren verwendungen
|
|
JP2006522811A
(ja)
|
2003-04-09 |
2006-10-05 |
ジェネンテック・インコーポレーテッド |
ＴＮＦαインヒビターに対して不十分な反応を示す患者の自己免疫疾患治療法
|
|
CA2566979A1
(en)
|
2004-06-04 |
2005-12-15 |
Genentech, Inc. |
Use of a cd20 antibody in treatment of multiple sclerosis
|
|
WO2006089133A2
(en)
|
2005-02-15 |
2006-08-24 |
Duke University |
Anti-cd19 antibodies and uses in oncology
|
|
US20060281680A1
(en)
|
2005-03-10 |
2006-12-14 |
Genentech, Inc. |
Methods and compositions for modulating vascular integrity
|
|
WO2006117782A2
(en)
|
2005-05-04 |
2006-11-09 |
Quark Pharmaceuticals, Inc. |
Recombinant antibodies against cd55 and cd59 and uses thereof
|
|
EP2221316A1
(en)
|
2005-05-05 |
2010-08-25 |
Duke University |
Anti-CD19 antibody therapy for autoimmune disease
|
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
|
EP2540741A1
(en)
|
2006-03-06 |
2013-01-02 |
Aeres Biomedical Limited |
Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
|
CA2685465C
(en)
|
2007-05-07 |
2020-02-25 |
Medimmune, Llc |
Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
|
EP3808348A1
(en)
|
2007-09-14 |
2021-04-21 |
Biogen MA Inc. |
Compositions and methods for the treatment of progressive multifocal leukoencephalopathy (pml)
|
|
EP2225275A4
(en)
|
2007-11-28 |
2013-04-03 |
Medimmune Llc |
PROTEIN FORMULATION
|
|
CA2723614C
(en)
|
2008-05-16 |
2015-07-14 |
Genentech, Inc. |
Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
|
|
TW201438738A
(zh)
|
2008-09-16 |
2014-10-16 |
Genentech Inc |
治療進展型多發性硬化症之方法
|
|
US20100105620A1
(en)
|
2008-10-10 |
2010-04-29 |
Anaphore, Inc. |
Polypeptides that bind Trail-R1 and Trail-R2
|
|
ES2719496T3
(es)
|
2008-11-12 |
2019-07-10 |
Medimmune Llc |
Formulación de anticuerpo
|
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
|
EP2414391B1
(en)
|
2009-04-02 |
2018-11-28 |
Roche Glycart AG |
Multispecific antibodies comprising full length antibodies and single chain fab fragments
|
|
EP2459591B1
(en)
|
2009-07-31 |
2014-08-20 |
Genentech, Inc. |
Inhibition of tumor metastasis using anti-g-csf-antibodies
|
|
KR20120108967A
(ko)
|
2009-09-16 |
2012-10-05 |
제넨테크, 인크. |
코일드 코일 및/또는 테더 함유 단백질 복합체 및 그의 용도
|
|
KR101557545B1
(ko)
|
2009-09-17 |
2015-10-06 |
에프. 호프만-라 로슈 아게 |
암 환자에서 진단 용도를 위한 방법 및 조성물
|
|
EP2486049A1
(en)
|
2009-10-06 |
2012-08-15 |
The Board Of Trustees Of The UniversityOf Illinois |
Human single-chain t cell receptors
|
|
WO2011060015A1
(en)
|
2009-11-11 |
2011-05-19 |
Genentech, Inc. |
Methods and compositions for detecting target proteins
|
|
US10584181B2
(en)
|
2009-12-04 |
2020-03-10 |
Genentech, Inc. |
Methods of making and using multispecific antibody panels and antibody analog panels
|
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
|
KR101860963B1
(ko)
|
2010-04-23 |
2018-05-24 |
제넨테크, 인크. |
이종다량체 단백질의 생산
|
|
MX340558B
(es)
|
2010-08-24 |
2016-07-14 |
F Hoffmann-La Roche Ag * |
Anticuerpos biespecificos que comprenden fragmento fv estabilizado con disulfuro.
|
|
US8580264B2
(en)
|
2010-11-08 |
2013-11-12 |
Genentech, Inc. |
Subcutaneously administered anti-IL-6 receptor antibody
|
|
WO2012085111A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
|
BR112013019499B1
(pt)
|
2011-02-04 |
2023-01-10 |
Genentech, Inc. |
Proteína heteromultimérica variante ou anticorpo igg modificado, método para produzir uma proteína heteromultimérica variante ou anticorpo igg modificado, composição, método para preparar uma proteína heteromultimérica e proteína heteromultimérica variante
|
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
|
SG10201606950RA
(en)
|
2011-03-31 |
2016-10-28 |
Genentech Inc |
Methods of administering beta7 integrin antagonists
|
|
WO2013013708A1
(en)
|
2011-07-26 |
2013-01-31 |
Fundació Institut D'investigació Biomèdica De Bellvitge |
Treatment of acute rejection in renal transplant
|
|
RU2014109985A
(ru)
|
2011-08-17 |
2015-09-27 |
Дженентек, Инк. |
Ингибирование ангиогенеза в рефрактерных опухолях
|
|
WO2013082511A1
(en)
|
2011-12-02 |
2013-06-06 |
Genentech, Inc. |
Methods for overcoming tumor resistance to vegf antagonists
|
|
WO2013101771A2
(en)
|
2011-12-30 |
2013-07-04 |
Genentech, Inc. |
Compositions and method for treating autoimmune diseases
|
|
KR20140119777A
(ko)
|
2012-01-31 |
2014-10-10 |
제넨테크, 인크. |
항-ig-e m1'' 항체 및 그의 사용 방법
|
|
KR20140127854A
(ko)
|
2012-02-10 |
2014-11-04 |
제넨테크, 인크. |
단일-쇄 항체 및 다른 이종다량체
|
|
EP3311847A1
(en)
|
2012-02-16 |
2018-04-25 |
Atyr Pharma, Inc. |
Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
|
|
KR20150023889A
(ko)
|
2012-06-27 |
2015-03-05 |
에프. 호프만-라 로슈 아게 |
2 개 이상의 상이한 결합 단위를 함유하는 맞춤-제작된 고도로 선별적이고 다중-특이적인 표적화 단위의 선별 및 제조 방법 및 이의 용도
|
|
BR112014028368A2
(pt)
|
2012-06-27 |
2017-11-14 |
Hoffmann La Roche |
método de produção de conjugado de região fc de anticorpo, conjugado de região fc de anticorpo e formulação farmacêutica
|
|
KR101850591B1
(ko)
|
2012-10-05 |
2018-04-19 |
제넨테크, 인크. |
염증성 장 질환의 진단 및 치료 방법
|
|
KR102182488B1
(ko)
|
2013-02-25 |
2020-11-24 |
제넨테크, 인크. |
약물 내성 akt 돌연변이체의 검출 및 치료를 위한 방법 및 조성물
|
|
WO2014151517A1
(en)
|
2013-03-15 |
2014-09-25 |
Intermune, Inc. |
Methods of improving microvascular integrity
|
|
AU2014241552B2
(en)
|
2013-03-27 |
2018-08-16 |
Genentech, Inc. |
Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
|
|
CA2939246A1
(en)
|
2014-03-27 |
2015-10-01 |
Genentech, Inc. |
Methods for diagnosing and treating inflammatory bowel disease
|
|
MX2016014409A
(es)
|
2014-05-06 |
2017-01-20 |
Genentech Inc |
Produccion de proteinas heteromultimericas usando celulas de mamifero.
|
|
MX2017003022A
(es)
|
2014-09-12 |
2017-05-12 |
Genentech Inc |
Anticuerpos anti-cll-1 e inmunoconjugados.
|
|
JP6721590B2
(ja)
|
2014-12-03 |
2020-07-15 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
多重特異性抗体
|
|
WO2016090210A1
(en)
|
2014-12-05 |
2016-06-09 |
Genentech, Inc. |
ANTI-CD79b ANTIBODIES AND METHODS OF USE
|
|
KR20170120601A
(ko)
|
2015-02-26 |
2017-10-31 |
제넨테크, 인크. |
인테그린 베타7 길항제 및 크론병을 치료하는 방법
|
|
JP6996983B2
(ja)
|
2015-06-16 |
2022-02-21 |
ジェネンテック， インコーポレイテッド |
抗ｃｌｌ－１抗体及び使用方法
|
|
EP4074730A1
(en)
|
2015-06-24 |
2022-10-19 |
F. Hoffmann-La Roche AG |
Anti-transferrin receptor antibodies with tailored affinity
|
|
WO2017004091A1
(en)
|
2015-06-29 |
2017-01-05 |
Genentech, Inc. |
Type ii anti-cd20 antibody for use in organ transplantation
|
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
|
CR20180149A
(es)
|
2015-10-02 |
2018-04-05 |
Hoffmann La Roche |
Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso
|
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
|
HRP20250052T1
(hr)
|
2015-10-06 |
2025-03-14 |
F. Hoffmann - La Roche Ag |
Postupak liječenja multiple skleroze
|
|
JP7008023B2
(ja)
|
2015-12-30 |
2022-01-25 |
ジェネンテック， インコーポレイテッド |
低減されたポリソルベート分解を有する製剤
|
|
EP3458101B1
(en)
|
2016-05-20 |
2020-12-30 |
H. Hoffnabb-La Roche Ag |
Protac antibody conjugates and methods of use
|
|
EP4252629A3
(en)
|
2016-12-07 |
2023-12-27 |
Biora Therapeutics, Inc. |
Gastrointestinal tract detection methods, devices and systems
|
|
WO2018112264A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
|
|
US11033490B2
(en)
|
2016-12-14 |
2021-06-15 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a JAK inhibitor and devices
|
|
EP3554346B1
(en)
|
2016-12-14 |
2024-01-31 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunosuppressant
|
|
EP3554345A1
(en)
|
2016-12-14 |
2019-10-23 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor
|
|
EP3554344A1
(en)
|
2016-12-14 |
2019-10-23 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a tlr modulator
|
|
CA3045475A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor released using an ingestible device
|
|
WO2018112240A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
|
|
WO2018112237A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
|
|
WO2018183932A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
|
|
US20210401895A1
(en)
|
2017-03-30 |
2021-12-30 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with live biotherapeutics
|
|
EP3600249A1
(en)
|
2017-03-30 |
2020-02-05 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
|
|
CA3054156A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
|
|
WO2019040680A1
(en)
|
2017-08-23 |
2019-02-28 |
Krzar Life Sciences |
IMMUNOPROTEASOME INHIBITORS AND IMMUNOSUPPRESSANT AGENT IN THE TREATMENT OF AUTOIMMUNE DISORDERS
|
|
RU2698048C2
(ru)
|
2017-10-03 |
2019-08-21 |
Закрытое Акционерное Общество "Биокад" |
МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
|
|
WO2019147824A1
(en)
|
2018-01-26 |
2019-08-01 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
|
|
JP7421504B2
(ja)
|
2018-06-01 |
2024-01-24 |
ビオラ・セラピューティクス・インコーポレイテッド |
胃腸のマイクロバイオームの検出および操作のためのデバイスおよびシステム
|
|
WO2019246317A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease or condition in a tissue originating from the endoderm
|
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
|
EP3870235A1
(en)
|
2018-10-24 |
2021-09-01 |
F. Hoffmann-La Roche AG |
Conjugated chemical inducers of degradation and methods of use
|
|
RU2724469C2
(ru)
|
2018-10-31 |
2020-06-23 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело, которое специфически связывается с cd20
|
|
CN116726361A
(zh)
|
2018-11-19 |
2023-09-12 |
比奥拉治疗股份有限公司 |
用生物治疗剂治疗疾病的方法和装置
|
|
EP3884276A2
(en)
|
2018-11-23 |
2021-09-29 |
Katholieke Universiteit Leuven |
Predicting a treatment response in inflammatory bowel disease
|
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
|
CA3106693A1
(en)
|
2019-02-06 |
2020-08-13 |
Sangamo Therapeutics, Inc. |
Method for the treatment of mucopolysaccharidosis type i
|
|
SG11202110776TA
(en)
|
2019-04-02 |
2021-10-28 |
Sangamo Therapeutics Inc |
Methods for the treatment of beta-thalassemia
|
|
CN110747267A
(zh)
*
|
2019-10-18 |
2020-02-04 |
佛山市第一人民医院（中山大学附属佛山医院） |
一种用于判断临床治疗对膜性肾病疗效的标志物
|
|
WO2021119482A1
(en)
|
2019-12-13 |
2021-06-17 |
Progenity, Inc. |
Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
|
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
|
WO2023086910A1
(en)
|
2021-11-12 |
2023-05-19 |
Genentech, Inc. |
Methods of treating crohn's disease using integrin beta7 antagonists
|
|
WO2024127332A1
(en)
|
2022-12-14 |
2024-06-20 |
Pheon Therapeutics Ltd |
Cytotoxic compounds
|